Sarepta Therapeutics (SRPT) Total Current Liabilities (2016 - 2025)
Sarepta Therapeutics (SRPT) has 15 years of Total Current Liabilities data on record, last reported at $921.4 million in Q3 2025.
- For Q3 2025, Total Current Liabilities rose 31.73% year-over-year to $921.4 million; the TTM value through Sep 2025 reached $921.4 million, up 31.73%, while the annual FY2024 figure was $731.7 million, 11.94% up from the prior year.
- Total Current Liabilities reached $921.4 million in Q3 2025 per SRPT's latest filing, roughly flat from $919.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $921.4 million in Q3 2025 and bottomed at $364.7 million in Q1 2021.
- Average Total Current Liabilities over 5 years is $587.1 million, with a median of $602.9 million recorded in 2022.
- Peak YoY movement for Total Current Liabilities: skyrocketed 61.45% in 2022, then dropped 25.24% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $452.7 million in 2021, then skyrocketed by 36.86% to $619.6 million in 2022, then rose by 5.5% to $653.7 million in 2023, then grew by 11.94% to $731.7 million in 2024, then increased by 25.93% to $921.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Total Current Liabilities were $921.4 million in Q3 2025, $919.9 million in Q2 2025, and $605.6 million in Q1 2025.